HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors

AIDS Research and Therapy

Volumn 2, Issue 1, 2005, Pages

  Fisher, Timothy S ^a,b   Joshi, Pheroze ^a   Prasad, Vinayaka R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVITY; ENZYME BINDING; GENE MUTATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

EID: 33744537658     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-2-8     Document Type: Article

References (36)

1. Goff SP: Retroviral reverse transcriptase: Synthesis, structure and function. JAIDS 1990, 3:817-831.
2. Skalka AM, Goff SP: Reverse transcriptase. 1993 edition. Plainview, NY, Cold Spring Harbor Laboratory; 1993:492.
3. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
4. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72(3):2422-2428.
5. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
6. Roberts JD, Bebenek K, Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
7. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard MJ, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
8. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
9. Richman DD: HIV Chemothrapy. Nature 2001, 410:995-1001.
10. Joshi PJ, Fisher TS, Prasad VR: Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 2003, 3(4):383-400.
11. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B: Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1 -based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004, 78(13):7079-7088.
12. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B: Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 2005, 16(1):17-25.
13. Coburn GA, Cullen BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002, 76(18):9225-9231.
14. Jacque JM, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature 2002, 418(6896):435-438.
15. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002, 20(5):500-505.
16. Novina CD, Murray MF, Dylochoorn DM, Beresford PJ, Riess J, Lee SK, Colman RG, Lieberman J, Shankar P, Sharp PA: siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8(7):681-686.
17. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510.
18. Chaloin L, Lehmann MJ, Sczakiel G, Restle T: Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 2002, 30(18):4001-4008.
19. Joshi P, Prasad VR: Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002, 76(13):6545-6557.
20. Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W: Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′FRNA aptamers. J Virol 2003, 77(23):12692-12698.
21. Tuerk C, MacDougal S, Gold L: RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A 1992, 89(15):6988-6992.
22. Burke DH, Scates L, Andrews K, Gold L: Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J Mol Biol 1996, 264:650-666.
23. Schneider DJ, Feigon J, Hostomsky Z, Gold L: High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995, 34:9599-9610.
24. Jaeger J, Restle T, Steitz TA: The Structure of HIV-1 Reverse Transcriptase Complexed with an RNA Pseudoknot Inhibitor. The EMBO Journal 1998, 17(15):4535.
25. Fisher TS, Joshi P, Prasad VR: Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. J Virol 2002, 76(8):4068-4072.
26. Fisher TS, Darden T, Prasad VR: Mutations proximal to the minor groove-binding track of human immunodeficiency virus type 1 reverse transcriptase differentially affect utilization of RNA versus DNA as template. J Virol 2003, 77(10):5837-5845.
27. Bebenek K, Beard WA, Darden TA, Li L, Prasad R, Luton BA, Gorenstein DG, Wilson SH, Kunkel TA: A minor groove binding track in reverse transcriptase [letter]. Nature Structural Biology 1997, 4(3):194-197.
28. Powell MD, Beard WA, Bebenek K, Howard KJ, Le Grice SF, Darden TA, Kunkel TA, Wilson SH, Levin JG: Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. J Biol Chem 1999, 274(28):19885-19893.
29. DeStefano JJ, Buiser RG, Mallaber LM, Bambara RA, Fay PJ: Human immunodeficiency virus reverse transcriptase displays a partially processive 3′ to 5′ endonuclease activity. J Biol Chem 1991, 266(36):24295-24301.
30. Schatz O, Mous J, Le Grice SF: HIV-1 RT-associated ribonuclease H displays both endonuclease and 3′ - 5′ exonuclease activity. Embo J 1990, 9(4):1171-1176.
31. Prasad VR, Lowy I, de los Santos T, Chiang L, Goff SP: Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1991, 88(24):11363-11367.
32. Arion D, Borokov G, Gu Z, Wainberg MA, Parniak MA: The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem 1996, 271:19860-19864.
33. Quan Y, Inouye P, Wainberg MA: Dominace of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing. The journal of biological chemistry 1998, 273(34):21918.
34. Kew Y, Qingbin S, Prasad VR: Subunit-selective mutagenesis of Glu-89 residue in human immunodeficiency virus reverse transcriptase. Contribution of p66 and p51 subunits to nucleoside analog sensitivity, divalent cation preference, and steady state kinetic properties. J Biol Chem 1994, 269(21):15331-15336.
35. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara RA: Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. Journal of Biological Chemistry 1997, 272(17):11157-11164.
36. Schatz O, Cromme FV, Gruninger-Leitch F, Le Grice SFJ: Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNAse H function. FEBS Lett 1989, 257:311-314.